Published in Mol Med on February 01, 2002
APP processing in Alzheimer's disease. Mol Brain (2011) 2.02
Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener (2011) 1.58
Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity. Hum Mol Genet (2009) 1.46
Physiological functions of APP family proteins. Cold Spring Harb Perspect Med (2012) 1.44
Neuronal brain-derived neurotrophic factor is synthesized in excess, with levels regulated by sortilin-mediated trafficking and lysosomal degradation. J Biol Chem (2011) 1.09
Trafficking regulation of proteins in Alzheimer's disease. Mol Neurodegener (2014) 1.08
Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease. J Neurol Sci (2005) 1.06
Functions of the APP gene family in the nervous system: insights from mouse models. Exp Brain Res (2011) 1.05
MicroRNA-144 is regulated by activator protein-1 (AP-1) and decreases expression of Alzheimer disease-related a disintegrin and metalloprotease 10 (ADAM10). J Biol Chem (2013) 0.99
Comparative analysis of single and combined APP/APLP knockouts reveals reduced spine density in APP-KO mice that is prevented by APPsα expression. Acta Neuropathol Commun (2014) 0.95
S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10. PLoS One (2009) 0.95
Expression of the anti-amyloidogenic secretase ADAM10 is suppressed by its 5'-untranslated region. J Biol Chem (2010) 0.94
ADAM10 expression and promoter haplotype in Alzheimer's disease. Neurobiol Aging (2012) 0.91
Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer's disease. Front Cell Neurosci (2015) 0.91
Translational repression of the disintegrin and metalloprotease ADAM10 by a stable G-quadruplex secondary structure in its 5'-untranslated region. J Biol Chem (2011) 0.90
Constitutive α- and β-secretase cleavages of the amyloid precursor protein are partially coupled in neurons, but not in frequently used cell lines. Neurobiol Dis (2012) 0.90
Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease. Neurobiol Aging (2010) 0.89
Alzheimer disease and platelets: how's that relevant. Immun Ageing (2012) 0.87
Biochemical studies in Normal Pressure Hydrocephalus (NPH) patients: change in CSF levels of amyloid precursor protein (APP), amyloid-beta (Aβ) peptide and phospho-tau. J Psychiatr Res (2010) 0.86
The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer's disease. Future Sci OA (2015) 0.86
Regulation of α-secretase ADAM10 expression and activity. Exp Brain Res (2011) 0.85
Activation of peroxisome proliferator-activated receptor α stimulates ADAM10-mediated proteolysis of APP. Proc Natl Acad Sci U S A (2015) 0.83
Platelets, a reliable source for peripheral Alzheimer's disease biomarkers? Acta Neuropathol Commun (2014) 0.82
Platelets and Alzheimer's disease: Potential of APP as a biomarker. World J Psychiatry (2012) 0.81
The Functional Maturation of A Disintegrin and Metalloproteinase (ADAM) 9, 10, and 17 Requires Processing at a Newly Identified Proprotein Convertase (PC) Cleavage Site. J Biol Chem (2015) 0.80
Coated-platelets correlate with disease progression in Alzheimer disease. J Neurol (2007) 0.80
Soluble interleukin-6 receptor levels and risk of dementia: one more signpost on a long road ahead. J Am Geriatr Soc (2014) 0.79
Association of ADAM10 and CAMK2A polymorphisms with conduct disorder: evidence from family-based studies. J Abnorm Child Psychol (2011) 0.79
Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and Gamma. Front Neurosci (2016) 0.79
Withanolide A and asiatic acid modulate multiple targets associated with amyloid-beta precursor protein processing and amyloid-beta protein clearance. J Nat Prod (2010) 0.78
Cerebrospinal Aβ11-x and 17-x levels as indicators of mild cognitive impairment and patients' stratification in Alzheimer's disease. Transl Psychiatry (2013) 0.78
Transmembrane Amyloid-Related Proteins in CSF as Potential Biomarkers for Alzheimer's Disease. Front Neurol (2015) 0.78
Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease. Mov Disord (2015) 0.77
Thioredoxin-80 is a product of alpha-secretase cleavage that inhibits amyloid-beta aggregation and is decreased in Alzheimer's disease brain. EMBO Mol Med (2012) 0.76
Artificial neural networks allow the use of simultaneous measurements of Alzheimer disease markers for early detection of the disease. J Transl Med (2005) 0.76
New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer's disease. BMC Neurosci (2012) 0.76
Decreased platelet APP isoform ratios in autosomal dominant Alzheimer's disease: baseline data from a DIAN cohort subset. Curr Alzheimer Res (2015) 0.75
Pathophysiological Function of ADAMTS Enzymes on Molecular Mechanism of Alzheimer's Disease. Aging Dis (2016) 0.75
Not just amyloid: physiological functions of the amyloid precursor protein family. Nat Rev Neurosci (2017) 0.75
Expression and Processing of Amyloid Precursor Protein in Vascular Endothelium. Physiology (Bethesda) (2017) 0.75
Harnessing the natural inhibitory domain to control TNFα Converting Enzyme (TACE) activity in vivo. Sci Rep (2016) 0.75
Regulation of Alpha-Secretase ADAM10 In vitro and In vivo: Genetic, Epigenetic, and Protein-Based Mechanisms. Front Mol Neurosci (2017) 0.75
Fluorescent Analogue of Batimastat Enables Imaging of α-Secretase in Living Cells. ACS Chem Neurosci (2015) 0.75
Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol (2007) 3.25
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
Loss of sight and sound. Could it be the hip? Lancet (2009) 2.43
Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain (2011) 2.13
Migraine mediates the influence of C677T MTHFR genotypes on ischemic stroke risk with a stroke-subtype effect. Stroke (2007) 2.02
A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain (2011) 1.89
Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol (2005) 1.82
Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. Stroke (2003) 1.81
JNK3 perpetuates metabolic stress induced by Aβ peptides. Neuron (2012) 1.80
Trigeminal small-fiber sensory neuropathy causes burning mouth syndrome. Pain (2005) 1.73
Regulation of dopamine D1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-D-aspartate receptors. J Biol Chem (2003) 1.55
A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat (2013) 1.53
Endothelial nitric oxide synthase (Glu298Asp) polymorphism is an independent risk factor for migraine with aura. Headache (2006) 1.52
Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem (2012) 1.52
Disulfiram neuropathy: two cases of distal axonopathy. Clin Toxicol (Phila) (2008) 1.47
Hyperhomocysteinemia: a potential risk factor for cervical artery dissection following chiropractic manipulation of the cervical spine. J Neurol (2002) 1.44
Evidence of white matter changes on diffusion tensor imaging in frontotemporal dementia. Arch Neurol (2007) 1.42
Outcomes of Alzheimer's disease treatment: the Italian CRONOS project. Int J Geriatr Psychiatry (2003) 1.40
Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. J Clin Invest (2008) 1.37
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci (2006) 1.34
Conversion of amnestic Mild Cognitive Impairment to dementia of Alzheimer type is independent to memory deterioration. Int J Geriatr Psychiatry (2007) 1.34
Peptidyl-prolyl cis-trans isomerase Pin1 in ageing, cancer and Alzheimer disease. Expert Rev Mol Med (2011) 1.28
Essential role of Pin1 in the regulation of TRF1 stability and telomere maintenance. Nat Cell Biol (2008) 1.27
Synaptic activity controls dendritic spine morphology by modulating eEF2-dependent BDNF synthesis. J Neurosci (2010) 1.25
Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord (2011) 1.25
Synapse-associated protein-97 mediates alpha-secretase ADAM10 trafficking and promotes its activity. J Neurosci (2007) 1.23
First steps towards the genetic manipulation of Mycoplasma agalactiae and Mycoplasma bovis using the transposon Tn4001mod. Int J Med Microbiol (2005) 1.20
Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors. Int J Geriatr Psychiatry (2007) 1.19
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain (2008) 1.19
Interleukin-1 beta released by gp120 drives neural death through tyrosine phosphorylation and trafficking of NMDA receptors. J Biol Chem (2006) 1.16
Decreased NR2B subunit synaptic levels cause impaired long-term potentiation but not long-term depression. J Neurosci (2009) 1.16
New targets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol (2006) 1.15
Course and management of allogeneic stem cell transplantation in patients with mitochondrial neurogastrointestinal encephalomyopathy. J Neurol (2012) 1.15
Pin1 in Alzheimer's disease: multiple substrates, one regulatory mechanism? Biochim Biophys Acta (2007) 1.13
Calcium/calmodulin-dependent protein kinase II phosphorylation drives synapse-associated protein 97 into spines. J Biol Chem (2004) 1.13
Thalamic infarcts in young adults: relationship between clinical-topographic features and pathogenesis. Eur Neurol (2002) 1.11
Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68. PLoS One (2011) 1.11
Cumulative effect of predisposing genotypes and their interaction with modifiable factors on the risk of ischemic stroke in young adults. Stroke (2005) 1.11
Reduction in retinal nerve fiber layer thickness in migraine patients. Neurol Sci (2012) 1.10
Neonatal exposure to brominated flame retardant BDE-47 reduces long-term potentiation and postsynaptic protein levels in mouse hippocampus. Environ Health Perspect (2007) 1.09
Atypical phenotypes and clinical variability in a large Italian family with DYT1-primary torsion dystonia. Mov Disord (2006) 1.08
The Dickkopf-homolog 3 is expressed in tumor endothelial cells and supports capillary formation. Int J Cancer (2008) 1.08
Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int J Geriatr Psychiatry (2006) 1.07
CaMKII-dependent phosphorylation regulates SAP97/NR2A interaction. J Biol Chem (2003) 1.07
Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J Neurosci (2004) 1.06
Prevalence of patent foramen ovale in a large series of patients with migraine with aura, migraine without aura and cluster headache, and relationship with clinical phenotype. J Headache Pain (2005) 1.06
Pitfalls in diagnosing mitochondrial neurogastrointestinal encephalomyopathy. J Inherit Metab Dis (2011) 1.05
The role of mitochondria in neurodegenerative diseases. J Neurol (2011) 1.05
Neuropathology of mitochondrial diseases. Biosci Rep (2007) 1.05
QT dispersion and heart rate variability abnormalities in Alzheimer's disease and in mild cognitive impairment. J Am Geriatr Soc (2005) 1.04
Misplaced NMDA receptors in epileptogenesis contribute to excitotoxicity. Neurobiol Dis (2011) 1.04
Cerebral amyloid angiopathy-related hemorrhages. Neurol Sci (2008) 1.03
Phase-locked mutants of Mycoplasma agalactiae: defining the molecular switch of high-frequency Vpma antigenic variation. Mol Microbiol (2008) 1.03
Association between tau H2 haplotype and age at onset in frontotemporal dementia. Arch Neurol (2005) 1.02
Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients. J Neuroinflammation (2011) 1.02
Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels. J Neurooncol (2009) 1.02
A PIN1 polymorphism that prevents its suppression by AP4 associates with delayed onset of Alzheimer's disease. Neurobiol Aging (2010) 1.01
Calcium-calmodulin-dependent protein kinase II phosphorylation modulates PSD-95 binding to NMDA receptors. Eur J Neurosci (2006) 1.01
Prolyl isomerase Pin1 promotes amyloid precursor protein (APP) turnover by inhibiting glycogen synthase kinase-3β (GSK3β) activity: novel mechanism for Pin1 to protect against Alzheimer disease. J Biol Chem (2011) 1.00
Is frontotemporal lobar degeneration a rare disorder? Evidence from a preliminary study in Brescia county, Italy. J Alzheimers Dis (2010) 1.00
Blood cell markers in Alzheimer Disease: Amyloid Precursor Protein form ratio in platelets. Exp Gerontol (2009) 0.99
White matter changes in corticobasal degeneration syndrome and correlation with limb apraxia. Arch Neurol (2008) 0.99
Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J Neurochem (2004) 0.99
Differential impact of apathy and depression in the development of dementia in mild cognitive impairment patients. Dement Geriatr Cogn Disord (2009) 0.99
Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study. Cerebrovasc Dis (2010) 0.99
Synaptic localization and activity of ADAM10 regulate excitatory synapses through N-cadherin cleavage. J Neurosci (2010) 0.98
Granulin mutation drives brain damage and reorganization from preclinical to symptomatic FTLD. Neurobiol Aging (2011) 0.98
Distribution of interleukin-1 receptor complex at the synaptic membrane driven by interleukin-1β and NMDA stimulation. J Neuroinflammation (2011) 0.98
Small nerve fiber pathology in critical illness. PLoS One (2013) 0.97
Migraine and ischemic stroke: a debated question. J Cereb Blood Flow Metab (2008) 0.97
Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias. Neurobiol Aging (2011) 0.97
Subcortical and deep cortical atrophy in Frontotemporal Lobar Degeneration. Neurobiol Aging (2009) 0.97